A Phase I Clinical Study of Recombinant Humanized Monoclonal Antibody MIL95 Injection in the Treatment of Lymphomas and Advanced Malignant Solid Tumors
Latest Information Update: 16 Aug 2023
At a glance
- Drugs MIL 95 (Primary)
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Beijing Mabworks Biotech
- 09 Aug 2023 Planned End Date changed from 1 Nov 2023 to 1 Nov 2024.
- 06 Jun 2023 Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 22 Aug 2022 Planned End Date changed from 1 Nov 2022 to 1 Nov 2023.